Brigitte Rack

Brigitte Rack

Auto-generated profile, based on publicly available information

Brigitte Rack

Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
AHAndreas Hartkopf
Andreas Hartkopf
SBSara Yvonne Brucker
Sara Yvonne Brucker
Florin-Andrei TaranFlorin-Andrei Taran
Florin-Andrei Taran
NHNadia Harbeck
Nadia Harbeck
AAAlexandra von Au
Alexandra von Au
KPKlaus Pantel
Klaus Pantel

18 March 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
WJWolfgang Janni
Wolfgang Janni
TFThomas W. P. Friedl
Thomas W. P. Friedl
TYTracy C. Yab
Tracy C. Yab
FBFrancois-Clement Bidard
Francois-Clement Bidard
MCMassimo Cristofanilli
Massimo Cristofanilli
MLMINETTA LIU
MINETTA LIU
Purpose: The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different breast cancer subtypes and clinical settings. Experimental Design: In total, 4,436 individual patient-level data with CTC results from both baseline and one follow-up (CellSearch; Menarini Silicon Biosystems) were analyzed to evaluate the association between CTC detection and overall survival (OS) in the full patient cohort and separately for tumor and treatment types. Results: Using the cutoff ≥1 CTC for CTC positivity, 913 (20.6%) patients had 0 CTCs at both time points (neg/neg) and 325 (7.3%) and 1,189 (26.8%) patients converted from CTC negative to CTC positive (neg/pos) or vice versa (pos/neg), whereas 2,009 (45.3%) patients had at least one CTC at both time points (pos/pos). The median OS for the neg/neg, neg/pos, pos/neg, and pos/pos group was 45.6, 26.1, 32.3, and 17.3 months, respectively (P < 0.0001, global log-rank test). CTC responders (pos/neg) showed a lower risk of death compared with CTC nonresponders (pos/pos; HR, 0.48; 95% confidence interval, 0.44–0.53). Similar results were obtained in subgroup analyses according to hormone receptor and HER2 subtype, treatment type, and with a ≥5 CTC cutoff for CTC positivity. Conclusions: Follow-up CTC assessments strongly predict OS independently from tumor subtype and treatment. New randomized trials to define the clinical utility of CTC monitoring for risk stratification and as an early response marker in metastatic breast cancer are urgently needed.

6 November 2013 in Der Gynäkologe
Verified
Journal Article
Closed access
PDF file
JSJ. Salmen
J. Salmen
BRB. Rack
B. Rack
DVD. Varga
D. Varga
JHJens Bodo Huober
Jens Bodo Huober
WJWolfgang Janni
Wolfgang Janni

1 January 2008 in Breast Care
Verified
Journal Article
Open access
PDF file
VMVolkmar Müller
Volkmar Müller
RGRichard Greil
Richard Greil
Marcus SchmidtMarcus Schmidt
Marcus Schmidt
WJWolfgang Janni
Wolfgang Janni
BRBrigitte Rack
Brigitte Rack
PSPiero Sismondi
Piero Sismondi

3 June 2025
Verified
Other
Open access
PDF file
WJWolfgang Janni
Wolfgang Janni
TFThomas W. P. Friedl
Thomas W. P. Friedl
TYTracy C. Yab
Tracy C. Yab
FBFrancois-Clement Bidard
Francois-Clement Bidard
MCMassimo Cristofanilli
Massimo Cristofanilli
MLMINETTA LIU
MINETTA LIU
Supplementary Table 4: Comparisons of the probabilities of being CTC positive betweenHER2- positive/hormone receptor-positive and HER2-positive/hormone receptor-negative tumors according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no).

3 June 2025
Verified
Other
Open access
PDF file
WJWolfgang Janni
Wolfgang Janni
TFThomas W. P. Friedl
Thomas W. P. Friedl
TYTracy C. Yab
Tracy C. Yab
FBFrancois-Clement Bidard
Francois-Clement Bidard
MCMassimo Cristofanilli
Massimo Cristofanilli
MLMINETTA LIU
MINETTA LIU
Supplementary Figure 4. Kaplan-Meier plot of overall survival according to change in CTC status from baseline to first follow-up (cutoff for CTC positivity ≥1 CTC). (A) HER2-positive/hormone receptor-positive tumors; (B) HER2-positive/hormone receptor-negative tumors. Survival time is given as time since baseline CTC assessment in months. The P-values refers to the global log rank test with 3 degrees of freedom.